Exercise induced rhabdomyolysis

by Ružič Maja, Fabri Milotka, Pobor Marta, Jovelić Aleksandra, Lukač Damir
Published 2009-01-01

The occurrence of liver steatosis in patients with chronic hepatitis C - the experience of the Clinical Center of Vojvodina

by Preveden Tomislav, Ružić Maja, Kovačević Nadica, Pete Maria, Fabri Milotka
Published 2018-01-01

Importance of adherence for efficacy of hepatitis C combined therapy

by Nožić Darko, Delić Dragan, Božić Milena, Fabri Milotka, Svorcan Petar, Konstantinović Ljiljana
Published 2013-01-01

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia

by Božić Milena, Bojović Ksenija, Fabri Milotka, Nožić Darko, Trkulja Bojan, Milošević Ivana
Published 2012-01-01

Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with Pegylated interferon alfa-2a and ribavirin

by Fabri Milotka, Ružić Maja, Lendak Dajana, Preveden Tomislav, Fabri Izabela, Petrić Vedrana
Published 2013-01-01

Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy

by Ružić Maja, Fabri Milotka, Preveden Tomislav, Bačulov Katarina, Pete Maria, Stojšin Anja
Published 2018-01-01

Visceral leishmaniasis as a cause of postpartum pyrexia — case report

by Milosevic Stevan, Bogavac Mirjana, Malenkovic Goran, Fabri Milotka, Ruzic Maja, Dugandzija Tihomir
Published 2013-04-01

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study

by Ružić Maja, Fabri Milotka, Stojanoska Medić Milica, Bajkin Ivana, Turkulov Vesna, Abenavoli Ludovico
Published 2017-01-01

Treatment of chronic hepatitis C among injecting drug users: A 5-year follow-up

by Ruzić Maja, Fabri Milotka, Preveden Tomislav, Kiralj Katarina, Mikić Stefan Sandra, Vukadinov Tatjana
Published 2013-01-01

Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users

by Ružić Maja, Fabri Milotka, Klašnja Biljana, Pobor Marta, Švarc Daniela, Jovelić Aleksandra, Fabri Izabela
Published 2010-01-01

Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia

by Simonović-Babić Jasmina, Bojović Ksenija, Fabri Milotka, Kostić Velimir, Jovanović Maja, Mijailović Željko, Svorcan Petar, Janković Goran
Published 2015-01-01

Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia

by Simonović-Babić Jasmina, Bojović Ksenija, Fabri Milotka, Cvejić Tatjana, Svorcan Petar, Nožić Darko, Jovanović Maja, Škrbić Ranko, Stojiljković Miloš P., Mijailović Željko
Published 2019-01-01